reason report
bottom line morn announc nomin
three new director stand behalf current board
manag june annual meet nomin
would increas compani board director
new appointe john chiminski william hawkin
jesu manta see bio three appointe bring
strong strateg oper expertis board investor
like question whether individu abl influenc
compani notori cautiou boardroom appear
new appoint prompt sharehold activ
dissatisfact understand given stock dismal
perform aducanumab develop failur believ
dissatisfact stem aducanumab failur
also absenc strong prepar possibl
failur lack portfolio high-prob
high-valu late stage program complement aducanumab instead
accumul program outsid alzheim diseas
compani valuat heyday compani next biggest
invest aducanumab variat theme
elenbecestat concentr risk overal portfolio
compani continu fund beta amyloid program today
new director nomin step forward would also
like see key director chairman announc retir
board ultim chang strategi direct manag
give us confid much need turnaround underway
otherwis distinguish director run risk mere dress
cautiou strategi philosophi alreadi prevail
written elsewher believ first
step forward end pain costli fruitless
invest target mechan explan
alzheim diseas share compani enthusiasm
target basi promis phase ii trial like
believ aducanumab best design version mani
molecul explor reduc beta amyloid
engag emerg trial best design care
optim studi launch set demonstr
reduct protein could revers slow moder
diseas recent confirm aducanumab
job studi reduc amyloid expect brain
treat patient unfortun reduct associ
meaning clinic improv henc decis halt trial
given outcom believ investor board
insist halt compani amyloid program
well thu save anoth expens free
manag time attent program
background investor ask biogen
manag step larg late stage invest
pleas refer page import disclosur price chart analyst certif
field neurosci time mean certain
invest success rel lack
program compani portfolio investor would like see one
acquir next month meantim find
hard identifi investor agre manag view
attract compani stock current rang board
recent decis add anoth share repurchas fund
endear compani manag board investor
new director profil bloomberg googl linkedin
mr chiminski age serv chief execut offic
inc sinc march chairman sinc
octob also serv presid inc
februari prior mr chiminski serv chief
execut offic presid medic diagnost
ltd octob march join ge medic system
mmp program held seri cross-funct
leadership posit manufactur engin includ
vice-president gm ge healthcar global magnet reson busi
vice-president gm global healthcar servic
mr chiminski serv director graham packag hold
compani inc djo global
mr chiminski substanti expertis advis manag
compani variou segment healthcar industri especi
medic technolog medic devic area signific experi
overse day-to-day busi oper healthcar compani
mr chiminski receiv michigan state univers
purdu univers electr engin well
manag kellogg school manag
mr hawkin age serv senior advis ew healthcar
partner prior ew healthcar partner serv ceo
presid immucor prior immucor mr
held variou senior leadership role
retir chairman ceo origin join
intervent cardiolog compani novost
serv presid ceo prior novost mr hawkin serv
senior leadership role follow compani ethicon endo-
surgeri inc unit guidant corpor januari
octob ivac corpor johnson johnson
 co mr hawkin began medic technolog career
carolina medic electron
mr hawkin success entrepreneur healthcar
three decad experi leadership medic technolog
medic devic pharmaceut healthcar invest
mr hawkin current serv director follow compani
organ duke univers truste bioventu immucor nae
virtu lab
mr hawkin dual degre electr biomed engin
duke univers univers virginia
darden school busi
mr manta age serv manag gener
manag strategi offer global busi servic
gb sinc prior role serv manag
gener manag busi consult gener manag
global process servic
mr manta live brazil led global busi servic latin
america earlier career serv partner vice-president
gener busi mobil busi solut prior join mr
manta partner pricewaterhousecoop consult
manag procter gambl
mr manta global recogn thought leadership
intersect busi technolog signific
experi leadership digit cognit analyt cloud
solut enterpris applic busi process practic
degre telecommun softwar engin
busi administr polytechn univers madrid
geoffrey porg mbb certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori biogen inc
leerink place market perform rate februari
creat bluematrix
price target base simpl averag three approach believ reason
basi valu stock today approach price earn price sale dcf price earn
approach appli current multipl depress larg cap healthcar celg compani
ep forecast produc one-year price target price sale approach use
current averag price sale slow grow larg cap biopharma stock celg
appli revenu forecast produc price target lastli dcf take
present valu forecast annual free cash flow assum valu termin cash
flow base termin growth rate discount compani cost capit present valu
averag approach current one-year price target
risk valuat
risk view outlook valuat includ major chang price reimburs
coverag label compani exist treatment multipl sclerosi tysabri avonex plegridi tecfidera
success develop rapid market share gain competitor product class success
gener challeng tecfidera intellectu properti posit alter ahead expect risk
includ disappoint question result on-going trial import develop program
opportun better perform valu includ strong result midstag pipelin includ
novel pain treatment vixotrigin anti-lingo myelin restor product opicinumab success progress
compani co-develop alzheim diseas treatment eisai ban
rate price target histori medtron plc
leerink place market perform rate jan
creat bluematrix
price target appli price-to-earnings multipl ep estim assum
share sustain current multipl ep estim though believ could
eventu return path consist mid-single-digit top-lin growth -- rtg big piec growth
acceler -- remain sidelin pend clariti cvg sale abil absorb/
move past on-going headwind ramp key pipelin product surgic robot minim
therapi group mitg time less certain see limit multipl expans
mid-single-digit growth trajectori larg predic new product launch sustain trend without
risk
risk valuat
risk valuat includ continu signific spine market spine sale declin market fail regain
deliv product pipelin failur success execut cost save initi
rate price target histori johnson johnson
leerink place outperform rate januari
creat bluematrix
next month believ share trade price target price target appli
price-to-earnings multipl ep estim share current trade ep estim
large-cap med-tech group rang price target
assum see multipl expans line broader comp group compani manag
top-lin headwind continu drive oper leverag -- posit sustain
ep out-performance view total return capabl attract increasingli volatil stock market
environ like attract fund riskier area
risk valuat
risk includ failur success integr auri potenti futur acquisit failur resolv
outstand consum consent decre success re-launch product product recal failur
advanc late-stag pipelin success launch new product protract recoveri procedur volum
trend lack real macroeconom recoveri
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
